Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

VivoSim Labs, INC. Director's Dealing 2021

Mar 10, 2021

35369_dirs_2021-03-10_895e6bc5-843e-4c44-8228-ab676d8d9975.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ORGANOVO HOLDINGS, INC. (ONVO)
CIK: 0001497253
Period of Report: 2021-03-08

Reporting Person: Murphy Keith (Director, Executive Chairman)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-03-08 Common Stock A 20000 $0.00 Acquired 66320 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-03-08 Stock Option (Right to Buy) $10.27 A 45000 Acquired 2031-03-08 Common Stock (45000) Direct
2021-03-08 Stock Option (Right to Buy) $10.27 A 60000 Acquired 2031-03-08 Common Stock (60000) Direct
2021-03-08 Stock Option (Right to Buy) $10.27 A 60000 Acquired 2031-03-08 Common Stock (60000) Direct

Footnotes

F1: The reported securities are represented by restricted stock units, 25% of which shall vest on March 8, 2022 and the remaining shares vest in 12 equal quarterly installments thereafter.

F2: 25% of the option shares vest and become exercisable on March 8, 2022 and the remaining shares vest in 12 equal quarterly installments thereafter.

F3: The option becomes exercisable, if at all, if the 45-day moving average closing price of Organovo Holdings, Inc.'s common stock on The Nasdaq Stock Market LLC exceeds $20.00 per share.

F4: The option becomes exercisable, if at all, if the 45-day moving average closing price of Organovo Holdings, Inc.'s common stock on The Nasdaq Stock Market LLC exceeds $25.00 per share.